CG Oncology, Inc. Common stock
NASDAQ:CGONBiotechnology
+$1.35 today
- Market cap
- $7.15B
- Beta
- 0.31
- P/E (TTM)
- -28.0
- EPS (TTM)
- -$2.21
Volume 1.79M
Average 1.08M
CGON Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CG Oncology, Inc. Common stockNASDAQ: CGON
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income grows, but more slowly than its trailing trend
Q3 FY2026 net income of $56.89M (cash outflow) rose 29.9% year over year, behind the +56.8% change in trailing-twelve-month net income. Sequentially, it fell 28.0% from the prior quarter. Over 3 fiscal years it compounded at +65.6% a year.
Context
- Net income amounted to 3985.0% of revenue in FY2025, down 3744.5 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 9 analysts of -$235.51M (+46.3%) for the fiscal year ending Dec 2026, a slowdown from the +82.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$56.89M-28.0% QoQ
- Last fiscal yearDec 2025
- -$161M+82.9% YoY
- LTMSep 2026
- -$237.46M+56.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +29.9% | +55.0% | +25.1 pp |
| 1 year | +82.9% | +46.3% | -36.6 pp |
| 3-year CAGR | +65.6% | -26.5% | -92.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (161M) USD
- Year-over-year change
- -82.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (161M) | -82.9% |
| FY2024 | 2024-12-31 | (88.04M) | -81.1% |
| FY2023 | 2023-12-31 | (48.61M) | -37.1% |
| FY2022 | 2022-12-31 | (35.44M) | -176.1% |
| FY2021 | 2021-12-31 | (12.84M) | — |
Net Income vs competitors
How CGON compares with its peers on the latest reported figures
- CGON's LTM Sep 2026 net income of $237.46M is the 2nd largest of the 3 companies compared; the peer median is $621.47M.
- Its year-over-year change of +56.8% is the 2nd highest of 3, against a peer median of +107.3%.
- Net income amounts to 3851.1% of revenue for CGON, versus a peer median of 351.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.11B | +218.3% | -5.5% | 607.8% | |
| LTM Sep 2026 | $237.46M | +56.8% | +65.6% | 3851.1% | |
| LTM Mar 2026 | $133.23M | -3.8% | +11.8% | 94.8% | |
| Peer median (excluding CGON) | $621.47M | +107.3% | +3.2% | 351.3% | |
Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.84M) | (35.44M) | (48.61M) | (88.04M) | (161M) |
| Depreciation & Amortization | 10K | 15K | 17K | 32K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.11M | 676K | 1.53M | 11.4M | 26.68M |
| Change in Working Capital | (1.97M) | 4.44M | 3.44M | 2.91M | 2.28M |
| Accounts Receivables | 0 | 0 | 0 | (689K) | (320K) |
| Inventory | 0 | 0 | 0 | 0 | (444K) |
| Accounts Payables | 578K | (18K) | 2.01M | 3.28M | (1.64M) |
| Other Working Capital | (2.55M) | 4.46M | 1.43M | 320K | 4.68M |
| Other Non-Cash Items | 30K | 509K | (2.06M) | (5.01M) | (1.75M) |
| Operating Cash Flow | (13.65M) | (29.8M) | (45.68M) | (78.71M) | (132.35M) |
| Capital Expenditures | (97K) | (14K) | 0 | (234K) | (134K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (21.97M) |
| Purchases of Investments | 0 | (55.34M) | (517.61M) | (1.05B) | (1.07B) |
| Sales of Investments | 0 | 0 | 396.42M | 745.41M | 844.14M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (97K) | (55.35M) | (121.2M) | (300.76M) | (245.82M) |
| Debt Repayment | 15.2M | 0 | (16.29M) | (365K) | 0 |
| Common Stock Issued | 245K | 166K | 2.08M | 629.47M | 153.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (3.42M) | (825K) | 0 |
| Financing Cash Flow | 15.45M | 119.69M | 87M | 628.28M | 153.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.7M | 34.54M | (79.88M) | 248.8M | (224.58M) |
| Free Cash Flow | (13.75M) | (29.82M) | (45.68M) | (78.95M) | (132.48M) |
CG Oncology, Inc. Common stock
NASDAQ:CGON
Intrinsic Alpha fair value
Locked
Current Price
$80.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.